Ascletis Pharma Inc.

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)
2020-09-09
Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen
2020-08-20
First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody
2020-08-17
Ascletis’ All-oral HCV Treatment Approved for Marketing in China
2020-07-31
Bridging Study in China Completed for NASH Drug Candidate ASC40
2020-07-20
ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial
2020-06-17
Ascletis’THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication
2020-05-13
Ascletis Receives IND Approval for its HIV Drug ASC09F
2020-04-13
Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020
2020-04-01
Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients
2020-03-25

2

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1